http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107823645-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107823645-B |
| titleOfInvention | BET inhibitor combined with NF-kB inhibitor for treating colorectal cancer and pharmaceutical composition |
| abstract | Epigenetic regulatory protein BET has been shown to regulate key oncogene transcription through binding with acetylated histones, and targeted inhibition of BET has anti-tumor significance. However, BET inhibitors (BET inhibitors, BETi) are resistant to some colorectal cancer cell lines, preventing clinical transformation applications of BETi. The invention discloses an application of a BETi inhibitor and an NF-kB inhibitor in preparation of a drug for treating colorectal cancer. The NF-kB inhibitor can enhance the treatment effect of BETi on the colorectal cancer through drug synergistic effect. The molecular mechanism is as follows: after the combined action of the medicaments, the down regulation of the c-myc gene is promoted, so that the transcription of the GADD45 gene is increased, and the increase of apoptosis and cell cycle block are mediated. The combined administration of the two inhibitors has obvious drug synergistic anti-tumor effect, and can be used as a novel treatment method for colorectal cancer. |
| priorityDate | 2017-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.